- Home
- KALA vs NOM Comparison
KALA vs NOM Comparison
Compare KALA & NOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- NOM
- Stock Information
- Founded
- KALA 2009
- NOM 1993
- Country
- KALA United States
- NOM United States
- Employees
- KALA N/A
- NOM N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- NOM Investment Managers
- Sector
- KALA Health Care
- NOM Finance
- Exchange
- KALA Nasdaq
- NOM Nasdaq
- Market Cap
- KALA 26.2M
- NOM 25.2M
- IPO Year
- KALA 2017
- NOM N/A
- Fundamental
- Price
- KALA $8.58
- NOM $10.92
- Analyst Decision
- KALA Strong Buy
- NOM
- Analyst Count
- KALA 3
- NOM 0
- Target Price
- KALA $14.00
- NOM N/A
- AVG Volume (30 Days)
- KALA 183.0K
- NOM 6.9K
- Earning Date
- KALA 08-08-2025
- NOM 01-01-0001
- Dividend Yield
- KALA N/A
- NOM 3.39%
- EPS Growth
- KALA N/A
- NOM N/A
- EPS
- KALA N/A
- NOM N/A
- Revenue
- KALA N/A
- NOM N/A
- Revenue This Year
- KALA N/A
- NOM N/A
- Revenue Next Year
- KALA N/A
- NOM N/A
- P/E Ratio
- KALA N/A
- NOM N/A
- Revenue Growth
- KALA N/A
- NOM N/A
- 52 Week Low
- KALA $2.92
- NOM $8.52
- 52 Week High
- KALA $11.20
- NOM $10.48
- Technical
- Relative Strength Index (RSI)
- KALA 67.01
- NOM 55.20
- Support Level
- KALA $7.38
- NOM $10.50
- Resistance Level
- KALA $7.71
- NOM $10.95
- Average True Range (ATR)
- KALA 0.79
- NOM 0.16
- MACD
- KALA 0.03
- NOM -0.01
- Stochastic Oscillator
- KALA 92.58
- NOM 67.74
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.